title: [Efficacy of combination therapy with EGFR-TKI and cytotoxic drug in lung adenocarcinoma already treated with EGFR-TKI].
abstract: OBJECITVE: To assess the efficacy of combination therapy with EGFR-TKI and a cytotoxic drug in lung adenocarcinoma already being treated with EGFR-TKI.
  
  
  METHODS
  Eight patients with adenocarcinoma who were treated with combination therapy of EGFR-TKI and a cytotoxic drug between April 2008 and December 2010 were retrospectively evaluated for response rate, disease-control rate, progression-free survival(PFS), time-to-treatment-failure(TTF)and overall survival(OS).
  
  
  RESULTS
  Among the 7 patients with tumor samples available, EGFR-mutations were detected in six.The median number of prior therapy regimens received by the patients was 5.All the patients had been treated before with both gefitinib and erlotinib.Among 8 patients, six showed stable disease, including three patients intolerant because of severe hematological toxicities, and 2 with progressive disease.The disease-control rate was 75%, and median TTF, PFS, and OS were 42 days, 84 days, and 495 days, respectively.
  
  
  CONCLUSIONS
  Combination therapy with EGFR-TKI and a cytotoxic drug after the failure of EGFR-TKI may be a useful therapeutic option for selected patients.
authors.affiliation: Dept. of Respiratory Medicine, National Center of Global Health and Medicine, Japan.
authors.forename: Satoshi
authors.initials: S
authors.lastname: Hirano
authors.forename: Yuichiro
authors.initials: Y
authors.lastname: Takeda
authors.forename: Yoshihisa
authors.initials: Y
authors.lastname: Hiraishi
authors.forename: Mari
authors.initials: M
authors.lastname: Higashino
authors.forename: Shinji
authors.initials: S
authors.lastname: Nakamichi
authors.forename: Satoru
authors.initials: S
authors.lastname: Ishii
authors.forename: Go
authors.initials: G
authors.lastname: Naka
authors.forename: Motoyasu
authors.initials: M
authors.lastname: Iikura
authors.forename: Shinyu
authors.initials: S
authors.lastname: Izumi
authors.forename: Haruhito
authors.initials: H
authors.lastname: Sugiyama
authors.forename: Nobuyuki
authors.initials: N
authors.lastname: Kobayashi
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy*; D000077192:Adenocarcinoma of Lung; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D066246:ErbB Receptors / Q000037:antagonists & inhibitors*; D000069347:Erlotinib Hydrochloride; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D008875:Middle Aged; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage; D011799:Quinazolines / Q000008:administration & dosage; D012189:Retrospective Studies; D016879:Salvage Therapy
chemical_list: D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D000069347:Erlotinib Hydrochloride; C512478:EGFR protein, human; D066246:ErbB Receptors